Revelation Biosciences Schedules Shareholder Vote on Reverse Stock Split to Maintain Nasdaq Listing
REVB is trading near its 52-week low of $0.875 (4.7% above the low).
Summary
Revelation Biosciences filed its definitive proxy statement, scheduling a shareholder meeting on June 24, 2026, to vote on a reverse stock split proposal with a wide ratio range (1-for-2 to 1-for-250) aimed at maintaining Nasdaq listing compliance.
Key Events · Corporate Governance and Compliance · REVB
-
Shareholder Meeting Scheduled
The definitive proxy statement sets the Annual Meeting of Stockholders for June 24, 2026, where key proposals will be voted on.
-
Reverse Stock Split Proposal
Shareholders will vote on authorizing the board to effect a reverse stock split with a ratio between 1-for-2 and 1-for-250 within one year, primarily to regain or maintain Nasdaq minimum bid price compliance.
-
History of Reverse Splits
This proposal follows previous reverse stock splits of 1-for-16 (January 2025), 1-for-3 (July 2025), and 1-for-4 (January 2026), indicating a recurring struggle with Nasdaq listing requirements.
-
Ongoing Going Concern Warning
The company's recent 10-Q (May 7, 2026) reiterated a going concern warning, highlighting its precarious financial position.
Analysis · REVB · Life Sciences
Revelation Biosciences has filed its definitive proxy statement, setting the stage for a critical shareholder vote on a reverse stock split. This action is crucial for the micro-cap company, which has a history of multiple reverse splits and ongoing going concern warnings, to maintain its Nasdaq listing. The wide potential ratio for the split (up to 1-for-250) underscores the severity of the company's stock price challenges and the significant potential for further share consolidation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REVB was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.88 to $40.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.